Statins Personalized - 04/03/12
, Kathryn M. Momary, PharmD, BCPS b, Yonghong Li, PhD a
Corresponding author. Celera Corporation, 1401 Harbor Bay Parkway, Alameda, CA 94502.Résumé |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor medications, commonly referred to as statins, are among the most widely prescribed medications. Variation in individual response to statins concerning low-density lipoprotein cholesterol reduction, clinical event benefit, and side effects has been observed. Some of this variability is attributed to demographic and environmental issues, chief of which is compliance. A large portion of the individual response to statin therapy is attributed to single nucleotide polymorphisms that have recently been elucidated, several of which seem to have clinical utility.
Le texte complet de cet article est disponible en PDF.Keywords : Genetic, Cholesterol, Statin, Coronary heart disease, Polymorphism
Plan
| Financial Disclosure and Conflict of Interest: Drs Superko and Li are employees of Celera Corporation. Celera is a gene discovery company and provides genetic testing services through Quest Diagnostics and Berkeley HeartLab. Drs Superko and Li own no stock and have no stock options in Quest Diagnostics, Celera, or Berkeley HeartLab. Dr Momary has an investigator-initiated grant from Pfizer. |
Vol 96 - N° 1
P. 123-139 - janvier 2012 Retour au numéro
Article précédent
- Genomics: Is It Ready for Primetime?
- Sonny Dandona, Alexandre F.R. Stewart, Robert Roberts
- Childhood Cholesterol Disorders: The Iceberg Base or Nondisease?
- Sarah D. de Ferranti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?